TTK Healthcare Limited (IN:TTKHLTCARE)
:TTKHLTCARE
TTKHLTCARE Stock Chart & Stats
₹1029.00
₹5.50(0.40%)
At close: 4:00 PM EST
₹1029.00
₹5.50(0.40%)
Day’s Range― - ―
52-Week Range₹737.00 - ₹1,402.00
Previous CloseN/A
Volume1.55K
Average Volume (3M)82.00
Market Cap
₹12.28B
Enterprise Value₹6.47B
Total Cash (Recent Filing)₹6.01B
Total Debt (Recent Filing)₹285.86M
Price to Earnings (P/E)34.8
Beta0.77
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)7.45
Shares Outstanding14,130,333
10 Day Avg. Volume50
30 Day Avg. Volume82
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.57
Price to Sales (P/S)1.91
P/FCF Ratio-99.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthLow leverage and a strong equity ratio provide durable financial flexibility. A healthy balance sheet and high ROE support investment in brands, capex, or targeted M&A, and increase resilience to sector downturns and working-capital pressure over the next 2–6 months.
Revenue Growth TrajectoryConsistent top-line expansion alongside robust gross margins indicates sustained demand and effective pricing/cost control in core products. This supports reinvestment in sales/marketing and product development, underpinning medium-term revenue continuity and brand equity.
Diversified Healthcare PortfolioA multi-segment model (branded formulations, consumer healthcare, condoms, devices and institutional channels) lowers reliance on any single market or product, smoothing revenue volatility and leveraging distribution relationships for durable market position and cross-sell opportunities.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow weakens the link between reported earnings and liquidity. Over 2–6 months this constrains funding for working capital, capex, dividends or buybacks, may necessitate external financing, and raises earnings-quality concerns.
Margin Pressure (EBITDA)A falling EBITDA margin signals operational cost pressures or loss of operating leverage. If sustained, this erodes the company’s ability to convert revenue into operating profit, limiting cash flow upside and making investments in growth or margin-restoration programs more urgent.
Earnings ContractionMaterial negative EPS growth reflects weakening profitability versus prior periods. Over the medium term this can reduce retained earnings availability for reinvestment, weaken stakeholder confidence, and limit management’s strategic optionality until margins or cash conversion recover.
TTK Healthcare Limited News
TTKHLTCARE FAQ
What was TTK Healthcare Limited’s price range in the past 12 months?
TTK Healthcare Limited lowest stock price was ₹737.00 and its highest was ₹1402.00 in the past 12 months.
What is TTK Healthcare Limited’s market cap?
TTK Healthcare Limited’s market cap is ₹12.28B.
When is TTK Healthcare Limited’s upcoming earnings report date?
TTK Healthcare Limited’s upcoming earnings report date is May 22, 2026 which is in 42 days.
How were TTK Healthcare Limited’s earnings last quarter?
TTK Healthcare Limited released its earnings results on Jan 22, 2026. The company reported ₹7.454 earnings per share for the quarter, beating the consensus estimate of N/A by ₹7.454.
Is TTK Healthcare Limited overvalued?
According to Wall Street analysts TTK Healthcare Limited’s price is currently Overvalued.
Does TTK Healthcare Limited pay dividends?
TTK Healthcare Limited pays a Annually dividend of ₹10 which represents an annual dividend yield of 0.95%. See more information on TTK Healthcare Limited dividends here
What is TTK Healthcare Limited’s EPS estimate?
TTK Healthcare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TTK Healthcare Limited have?
TTK Healthcare Limited has 14,130,333 shares outstanding.
What happened to TTK Healthcare Limited’s price movement after its last earnings report?
TTK Healthcare Limited reported an EPS of ₹7.454 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.839%.
Which hedge fund is a major shareholder of TTK Healthcare Limited?
Currently, no hedge funds are holding shares in IN:TTKHLTCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TTK Healthcare Limited
TTK Healthcare Limited engages in the animal welfare and human pharma product, consumer product, medical device, protective device, and food businesses in India and internationally. Its Animal Welfare segment deals in various therapeutic formulations and feed supplements for veterinary use. The company's Consumer Products segment is involved in the marketing and distribution of Woodward's Gripewater, EVA range of cosmetics, Good Home range of scrubbers, air fresheners, etc. its Medical Devices segment manufactures and distributes artificial heart valves; and develops orthopedic implants and instruments. The company's Protective Devices segment manufactures and markets male contraceptives and other allied products. Its Foods segment engages in the manufacturing and marketing of food products, including potato and cereal based pellets. The company's Others segment prints and publishes maps and atlases. Its Human Pharma segment deals in herbal and allopathic formulations for human use. The company was incorporated in 1958 and is headquartered in Chennai, India. TTK Healthcare Limited is a subsidiary of TT Krishnamachari & Co., Ltd.
Technical Analysis
Amrutanjan Health Care Limited
―
Bajaj Healthcare Ltd
―
SMS Pharmaceuticals Limited
―
Vimta Labs Limited
―
Windlas Biotech Ltd.
―